Brain Metastasis Screening in the Molecular Age

Abstract The incidence of brain metastases (BM) amongst cancer patients has been increasing due to improvements in therapeutic options and an increase overall survival. Molecular characterization tumors provided insights into the biology oncogenic drivers BM molecular subtype-based screening. Though there are currently some screening surveillance guidelines for BM, they remain limited. In this comprehensive review, we review present epidemiological data on their characterization, current guidelines. subtypes with highest EGFR-mutated NSCLC, BRCA1, TN, HER2+ breast cancers, BRAF-mutated melanoma. Furthermore, BMs more likely asymptomatically at diagnosis oncogene-addicted NSCLC European standards recommend frequent patients, clinical trials investigating HR+, HER2+, TN cancers. However, work is needed determine optimal other primary subtypes. With advent personalized medicine, revolutionized landscape treatment prognostication. Incorporating may allow physicians better identify high risk development improve patient outcomes.